Gilead Sciences launch one-pill, combination HIV treatment ‘Genvoya’
‘Genvoya,’ a one-pill, combination HIV treatment containing TAF(Tenofovir Alafenamide) for the first time, will be launched in Korea from February.
Tenofovir Alafenamide shows the antiviral effect that is similar to the existing tenofovir disoproxil fumarate(TDF) with the 90% lesser volume and i...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
